Last reviewed · How we verify
chlorobutanol, hexetidine
Chlorobutanol and hexetidine are antimicrobial agents that disrupt bacterial and fungal cell membranes and inhibit microbial growth.
Chlorobutanol and hexetidine are antimicrobial agents that disrupt bacterial and fungal cell membranes and inhibit microbial growth. Used for Oral rinse for antimicrobial and antiseptic purposes, Topical antimicrobial agent for minor wounds and oral hygiene.
At a glance
| Generic name | chlorobutanol, hexetidine |
|---|---|
| Also known as | Curasept® ADS 0.20%, Curaden Healthcare |
| Sponsor | Federico II University |
| Drug class | Antimicrobial preservative / topical antiseptic |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Oral Care / Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
Chlorobutanol is a halogenated alcohol that acts as a preservative and antimicrobial by denaturing proteins and disrupting cell membrane integrity in microorganisms. Hexetidine is a biguanide antimicrobial that interferes with bacterial and fungal cell wall synthesis and membrane function. Together, they provide broad-spectrum antimicrobial activity for topical and oral use.
Approved indications
- Oral rinse for antimicrobial and antiseptic purposes
- Topical antimicrobial agent for minor wounds and oral hygiene
Common side effects
- Local irritation or burning sensation
- Allergic contact dermatitis
- Taste disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chlorobutanol, hexetidine CI brief — competitive landscape report
- chlorobutanol, hexetidine updates RSS · CI watch RSS
- Federico II University portfolio CI